FcγRIIB is a T cell checkpoint in antitumor immunity

In the setting of cancer, T cells upregulate coinhibitory molecules that attenuate TCR signaling and lead to the loss of proliferative capacity and effector function. Checkpoint inhibitors currently in clinical use have dramatically improved mortality from melanoma yet are not effective in all patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Farley, Clara R., Morris, Anna B., Tariq, Marvi, Bennion, Kelsey B., Potdar, Sayalee, Kudchadkar, Ragini, Lowe, Michael C., Ford, Mandy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934918/
https://www.ncbi.nlm.nih.gov/pubmed/33616086
http://dx.doi.org/10.1172/jci.insight.135623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934918/
https://www.ncbi.nlm.nih.gov/pubmed/33616086
http://dx.doi.org/10.1172/jci.insight.135623

Ejemplares similares